TAI · 6949.TW
Pell Bio-Med Technology Co., Ltd.
NT$39.05NT$0.00 (0.0%)
Pell Bio-Med Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.38% below the high.
Loading market information…
TWO · 3176.TWO · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Medigen Biotechnology Corp.’s quoted price sits in the lower half of its reported 52-week range, 23.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Medigen Biotechnology Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated to inventing therapies for liver diseases and various forms of cancer. Its product portfolio includes advanced cell therapies like MAGICELL-NK, which leverages natural killer cells, and MAGICELL-GDT, a T-cell-based treatment. A significant pipeline asset for Medigen is OBP-301. This therapeutic has completed Phase I clinical trials for combination therapy in esophageal cancer in Japan. It is currently being evaluated in ongoing Phase I trials in Japan, combining it with immune checkpoint inhibitors (ICIs) for esophageal cancer, and has advanced to Phase II studies in the United States, investigating its use with ICIs for both esophageal and gastric cancer. Established in 1999, Medigen Biotechnology Corp. maintains its corporate headquarters in Taipei, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$39.05NT$0.00 (0.0%)
Pell Bio-Med Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.38% below the high.
NT$30.95NT$0.00 (0.0%)
Senhwa Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.46% below the high.
NT$20.80NT$0.00 (0.0%)
Gwo Xi Stem Cell Applied Technology Co. , Ltd’s quoted price sits in the lower half of its reported 52-week range, 28.03% below the high.
NT$18.70NT$0.00 (0.0%)
Lukas Biomedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.46% below the high.
